血栓通胶囊辅助治疗非缺血型视网膜静脉阻塞并黄斑水肿的疗效  

Adjuvant therapy of Xueshuantong capsule for macular edema due to non-ischemic retinal vein occlusion

作　　者：陈丹娜 吕秋荣 林桂英 CHEN Dan-na;LV Qiu-rong;LIN Gui-ying(Department of Ophthalmology,Affiliated Hospital of Guangdong Medical University,Zhanjiang 524000,China)

机构地区：[1]广东医科大学附属医院眼科,广东湛江524000

出　　处：《广东医科大学学报》2022年第3期312-315,共4页Journal of Guangdong Medical University

基　　金：湛江市非资助科技攻关计划项目(200924154540953)。

摘　　要：目的 观察复方血栓通胶囊联合玻璃体腔内注射康柏西普对非缺血型视网膜静脉阻塞(RVO)继发黄斑水肿的疗效。方法 69例单眼非缺血型RVO继发黄斑水肿患者,分别单纯接受玻璃体腔内注射康柏西普(A组,31例)或联合口服复方血栓通胶囊(B组,38例)治疗。比较两组术后1、2、3个月最佳矫正视力、黄斑厚度及注射次数。结果 两组最佳矫正视力、黄斑厚度差异无统计学意义(P>0.05),但B组注射次少于A组(P<0.05)。结论 复方血栓通胶囊可减少非缺血型RVO继发黄斑水肿患者康柏西普注射次数。Objective To observe the efficacy of compound Xueshuantong capsule(CXC) and intravitreal Conbercept in macular edema due to non-ischemic retinal vein occlusion(NIRVO). Methods Sixty-nine patients(69 eyes) with macular edema secondary to NIRVO were treated with intravitreal Conbercept(A group, n=31) or combined oral CXC(B group, n=38).The best corrected visual acuity(BCVA), macular thickness and injection number were compared between two groups at 1, 2and 3 months postoperation. Results Although BCVA and macular were comparable between two groups(P>0.05), injection number was lower in B group than in A group(P<0.05). Conclusion CXC can reduce the injection number of intravitreal Conbercept in patients with macular edema due to NIRVO.

关 键 词：视网膜静脉阻塞 黄斑水肿 康柏西普 复方血栓通胶囊 

分 类 号：R774.1[医药卫生—眼科]